Paper Review Records
全部论文审稿周期
25 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
63
天
PBPK‐Based Prediction of Oliceridine Exposure in Breast Milk and Relative Infant Dose During the First 24 h After Cesarean Delivery
作者
Yixi Ding; Ke Liu; Shuaishuai Zhang; Yanxu Zhang; Xin Tan; Weimin Xu展开收起
作者单位
1. School of Anesthesiology Shandong Second Medical University Weifang Shandong China; 2. Department of Anesthesiology Shengli Oilfield Central Hospital Dongying Shandong China展开收起
85
天
Simulation‐Based Evaluation of Busulfan Sampling Strategies in Adults and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
作者
Zhiyuan Tan; Federica R. Achini‐Gutzwiller; Arjan C. Lankester; Joost G. K. van der Hem; Peter A. von dem Borne; Dirk Jan. A. R. Moes; Tim Preijers展开收起
作者单位
1. Department of Clinical Pharmacy & Toxicology Leiden University Medical Center Leiden The Netherlands; 2. Division of Systems Pharmacology and Pharmacy Leiden Academic Center for Drug Research Leiden University Leiden The Netherlands; 3. Department of Pediatrics Leiden University Medical Center Leiden The Netherlands; 4. Department of Hematology Leiden University Medical Center Leiden The Netherlands; 5. Department of Hospital Pharmacy Rotterdam Erasmus Medical Center Rotterdam The Netherlands展开收起
215
天
Dose Selection for Ceftibuten Combined with Avibactam Tomilopil, a Potential Oral Alternative to Carbapenems for Patients with Complicated Urinary Tract Infections
作者
Siddhee A. Sahasrabudhe; Satoshi Shoji; Abhijeet S. Jakate; Bisrat K. Abraham; Sima S. Toussi; Benjamin J. Maligalig; Amanda S. Darekar; Sakambari Tripathy; Constantino Kantaridis; Josue K. Mfopou; Oxana Selivanova; Arthur Bergman; Negar Niki Alami; Ravi Shankar P. Singh展开收起
作者单位
1. Pfizer Inc. Cambridge MA USA; 2. Pfizer R&D Japan Tokyo Japan; 3. Pfizer Inc. New York NY USA; 4. Pfizer Inc. Pearl River NY USA; 5. Pfizer Inc. Makati City Philippines; 6. Pfizer R&D UK Ltd. Tadworth Surrey UK; 7. Pfizer Inc. South San Francisco CA USA; 8. Pfizer CRU Brussels Belgium; 9. Pfizer Inc. Groton CT USA展开收起
49
天
Bayesian‐Estimated Vancomycin AUC24 as a Near‐Term Renal Risk Signal after Therapeutic Drug Monitoring: A Multicenter Cohort Study
作者
Tran Van Anh; Bui Thi Tham; Tran Thi Ngan; Nguyen Duc Long,; Nguyen Huong Giang; Nguyen Hoang Anh; Vu Dinh Hoa; Hoang Van Dung; Nguyen Thi Thu Phuong展开收起
作者单位
1. Faculty of Pharmacy Hai Phong University of Medicine and Pharmacy Hai Phong Viet Nam; 2. Department of Pharmacy Hai Phong International Hospital Hai Phong Viet Nam; 3. Hanoi University of Pharmacy Hanoi Viet Nam; 4. Vietnam National Drug Information and Adverse Drug Reaction Monitoring Centre Hanoi Viet Nam; 5. Department of Internal Medicine Hai Phong International Hospital Hai Phong Viet Nam; 6. Department of Internal Medicine Hai Phong University of Medicine and Pharmacy Hai Phong Viet Nam展开收起
59
天
Tamoxifen Therapy Is Associated With Altered Intestinal P‐Glycoprotein Activity In Vivo
作者
Álef Machado Gomes Pego; Fernanda de Lima Moreira; Ana Flavia Mendes Batista; Adriana Rocha; Maria Paula Marques Pereira; Eduardo Barbosa Coelho; Jurandyr Moreira de Andrade; Geraldo Duarte; Vera Lucia Lanchote; João Paulo Bianchi Ximenez展开收起
作者单位
1. School of Pharmaceutical Sciences of Ribeirão Preto University of São Paulo Ribeirão Preto São Paulo Brazil; 2. Faculty of Pharmacy Federal University of Rio de Janeiro Rio de Janeiro Rio de Janeiro Brazil; 3. Ribeirão Preto Medical School University of São Paulo Ribeirão Preto São Paulo Brazil展开收起
69
天
PBPK Modeling of Esomeprazole to Support Adolescent Pharmacokinetic Extrapolation and Label Extension in Chinese Patients With Gastroesophageal Reflux Disease (GERD)
作者
Yuwen Jin; Junjie Ding; Xiaohan Hua; Wei Duan; Mo Chen; Zhaohui Zhou; Ramesh V Pandherpur; Jin Dong; Sharma Pradeep; Peiming Ma; Weifeng Tang; Diansong Zhou展开收起
作者单位
1. Clinical Pharmacology R&D China AstraZeneca Shanghai China; 2. Respiratory & Immunology R&D China AstraZeneca Shanghai China; 3. Biometrics and Data Science R&D China AstraZeneca Shanghai China; 4. Clinical Safety R&D China AstraZeneca Shanghai China; 5. Clinical Development BioPharmaceuticals R&D AstraZeneca Bengaluru India; 6. Clinical Pharmacology & Quantitative Pharmacology Clinical Pharmacology and Safety Sciences R&D, AstraZeneca Gaithersburg Maryland USA; 7. Clinical Pharmacology & Quantitative Pharmacology Clinical Pharmacology and Safety Sciences R&D, AstraZeneca Cambridge UK; 8. Clinical Pharmacology & Quantitative Pharmacology Clinical Pharmacology and Safety Sciences R&D, AstraZeneca Waltham Massachusetts USA展开收起
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿62 天
中位数65 天